The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Clinical pharmacokinetic-pharmacodynamic (PK/PD) modeling study of the novel dual PI3K/mTOR inhibitor BEZ235.
D. Bottino
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
J. Tabernero
Consultant or Advisory Role - Novartis (U)
H. A. Burris
No relevant relationships to disclose
C. Britten
No relevant relationships to disclose
L. C. Chen
No relevant relationships to disclose
J. C. Bendell
Consultant or Advisory Role - Novartis
O. Chiparus
Employment or Leadership Position - Novartis
V. Duval
Employment or Leadership Position - Novartis
E. Di Tomaso
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
C. Sarr
Employment or Leadership Position - Novartis
W. Hackl
Employment or Leadership Position - Novartis
J. Baselga
Consultant or Advisory Role - Novartis
J. Rodon Ahnert
Research Funding - Novartis